Emily Z. Hejazi

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial”.

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial

Journal of Investigative Dermatology(2022)10.1016/j.jid.2022.03.029

N/A

0.601DataRank · unranked

54 citations

Emily Z. Hejazi, S.M. Peña, Jessica S. Haber, Majid Zeidi, Nithin Reddy +10 more

Cardiovascular comorbidities are associated with dermatomyositis: A cross-sectional study in the All of Us Research Program

Journal of the American Academy of Dermatology(2023)10.1016/j.jaad.2023.12.037

N/A

0DataRank · unranked

2 citations

Keya Shah, Daniel R. Mazori, Avrom S. Caplan, Emily Z. Hejazi, Michael Garshick +2 more

Risk of interstitial lung disease in adult patients with dermatomyositis treated with methotrexate: A retrospective analysis of a prospective cohort

Journal of the American Academy of Dermatology(2025)10.1016/j.jaad.2025.01.002

N/A

0DataRank · unranked

0 citations

Hallie Carol, Rui Feng, A Hill, Laís Lopes Almeida Gomes, Emily Z. Hejazi +3 more